AbbVie's Imbruvica misses pancreatic cancer endpoints

AbbVie Inc. (NYSE:ABBV) said late Friday Imbruvica ibrutinib missed the co-primary endpoints in the Phase III RESOLVE (PCYC-1137) trial as part of a first-line combination treatment of metastatic pancreatic cancer.